Want to see SE:SYNACT full AI Analyst Report?
SYNACT Stock Chart & Stats
kr18.48
-kr0.02(-0.11%)
At close: 4:00 PM EDT
kr18.48
-kr0.02(-0.11%)
Day’s Range― - ―
52-Week Rangekr7.05 - kr25.30
Previous CloseN/A
Volume64.35K
Average Volume (3M)214.83K
Market Cap
kr915.15M
Enterprise Valuekr913.67
Total Cash (Recent Filing)kr65.78M
Total Debt (Recent Filing)kr1.07M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding53,330,242
10 Day Avg. Volume154,831
30 Day Avg. Volume214,829
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and a sizable equity base reduce solvency and refinancing risk, giving management flexibility to fund clinical programs. This structural balance-sheet strength extends runway relative to highly levered peers and supports execution on R&D over the next several months.
Focused Lead Asset (resomelagon / AP1189)A concentrated pipeline centered on a single mechanism (melanocortin activation) and a lead clinical asset concentrates resources and strategic focus. If clinical readouts progress, this focused R&D strategy can generate durable value and simplify go-to-market or partnership decisions.
Lean Operating StructureAn extremely small headcount implies a capital-efficient operating model that can leverage CROs and partners for trials. Lower fixed overhead reduces incremental cash burn, helping preserve runway from the existing equity base and supporting continued clinical development.
Bears Say
No Revenue / Sustained LossesThe company remains pre-commercial with no product revenue and large recurring net losses. Absent successful clinical milestones or licensing, this structural lack of top-line cash generation forces ongoing dependence on external capital and leaves long-term viability contingent on R&D success.
Negative Operating Cash Flow / Cash BurnConsistent negative operating and free cash flow materially depletes resources and creates a durable financing requirement. Even with some TTM improvement, continued burn will likely necessitate equity or debt raises, increasing dilution or financing risk for shareholders over the coming months.
Negative Return On EquityA deeply negative ROE signals poor capital efficiency and that deployed capital has not generated shareholder value. This structural weakness increases pressure to demonstrate clinical or commercial progress; until then, investor returns are likely to remain weak and value may erode.
SynAct Pharma AB News
SYNACT FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was kr7.05 and its highest was kr25.30 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is kr915.15M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 21 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on May 27, 2026. The company reported -kr0.476 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -kr0.476 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.848%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in SE:SYNACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―